An overview of the rare parotid gland cancer

Kimberley Ho, Helen Lin, David K. Ann, Peiguo G. Chu, Yun Yen

Research output: Contribution to journalReview articlepeer-review

57 Citations (Scopus)


Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

Original languageEnglish
Article number40
JournalHead and Neck Oncology
Issue number1
Publication statusPublished - Dec 1 2011


  • Parotid gland cancer
  • endosomal sorting complexes required for transport
  • epidermal growth factor receptor
  • multi-vesicular bodies
  • salivary gland cancer
  • targeted therapeutics
  • vacuolar protein sorting-associated protein 4B
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Oncology


Dive into the research topics of 'An overview of the rare parotid gland cancer'. Together they form a unique fingerprint.

Cite this